Valcyte 450mg
Original price was: ₨ 115,000.₨ 110,000Current price is: ₨ 110,000.
Brand Name: Roche / Genentech
Chemical Name: Valganciclovir Hydrochloride
Dosage Strength: 450mg film-coated tablets (60 tablets per bottle)
Rx / OTC: Rx
Valcyte 450mg by Roche/Genentech contains valganciclovir, a prodrug rapidly converted to ganciclovir, used to treat CMV retinitis in AIDS patients and prevent CMV disease in kidney, heart, and kidney-pancreas transplant recipients. It works by halting cytomegalovirus DNA replication inside infected cells, controlling but not eradicating the virus. Tablets must be taken with food and swallowed whole, never crushed due to the active ingredient’s potential teratogenicity and carcinogenicity. FDA-approved since 2001 and listed on the WHO Essential Medicines List.
Key Benefits of Valcyte 450mg
How It Works
- Valganciclovir is a prodrug. After oral administration, it is rapidly converted by intestinal and hepatic esterases to ganciclovir, the active antiviral agent.
- Inside CMV-infected cells, ganciclovir is phosphorylated first by the viral thymidine kinase, then by cellular kinases to ganciclovir triphosphate.
- Ganciclovir triphosphate inhibits CMV DNA polymerase and incorporates into viral DNA, halting viral replication.
- The oral bioavailability of valganciclovir is roughly 10 times higher than that of oral ganciclovir capsules, enabling effective outpatient therapy.
Dosage, Uses & Possible Side Effects
Dosage & Administration:
- CMV retinitis induction (adults): 900mg twice daily for 21 days.
- Maintenance: 900mg once daily.
- Transplant prophylaxis (adults): 900mg once daily, starting within 10 days of transplantation.
- Always take with food to maximise absorption. Do not crush or break tablets.
Uses:
- Treatment of cytomegalovirus (CMV) retinitis in adult patients with AIDS.
- Prevention of CMV disease in adult kidney, heart, and kidney-pancreas transplant recipients at high risk (donor CMV positive / recipient negative).
- Prevention of CMV disease in paediatric kidney transplant patients (4 months–16 years) and heart transplant patients (1 month–16 years) at high risk.
- Manufactured by Roche/Genentech, FDA-approved since 2001, and on the WHO List of Essential Medicines.
Possible Side Effects:
- Boxed warnings: severe haematologic toxicity (neutropenia, anaemia, thrombocytopenia), impaired fertility, fetal toxicity, and potential carcinogenicity.
- Common: diarrhoea, nausea, headache, fever, and anaemia.
- Regular monitoring of complete blood counts and serum creatinine is mandatory throughout treatment.
Customer Reviews
They have already used our services
Frequently Asked Questions
No. Tablets must be swallowed whole. The active ingredient is potentially teratogenic and carcinogenic, so direct skin contact with crushed tablet powder must be avoided.
No. Valcyte suppresses CMV replication and manages the disease but does not eradicate the virus. Long-term or maintenance therapy is often required in immunocompromised patients.
Women of reproductive potential must use effective contraception during treatment and for at least 30 days after. Men should use condoms during and for 90 days after treatment.
Store tablets at 25°C (excursions permitted 15°C–30°C) in a dry place.
Reviews
There are no reviews yet.